EGFR and non-small cell lung carcinoma: Indeed, Niederst and colleagues found that Rb was lost in 100% of tumor samples and cell lines derived from EGFR mutant non-small cell lung cancer patients harboring resistance to anti-EGFR tyrosine kinase inhibitors when small cell lung cancer (SCLC) characteristics are being acquired [48].